Treatment Outcome of Gamma Knife Radiosurgery for GH-Secreting Pituitary Tumors.
- Author:
Young Jin LIM
1
;
Yeong Ho CHOI
;
Won LEEM
;
Ki Taek LEE
;
Jun Seok KOH
;
Tae Sung KIM
;
Gook Ki KIM
;
Bong Arm RHEE
Author Information
1. Department of Neurosurgery, School of Medicine, Kyung Hee University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Acromegaly;
Gamma knife radiosurgery;
Pituitary adenoma;
Growth hormone
- MeSH:
Acromegaly;
Follow-Up Studies;
Growth Hormone;
Growth Hormone-Secreting Pituitary Adenoma;
Humans;
Pituitary Neoplasms*;
Radiosurgery*;
Treatment Outcome*;
Tumor Burden
- From:Journal of Korean Neurosurgical Society
2001;30(5):567-574
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: As for growth hormone(GH) secreting pituitary adenoma, it's remission should be declared on the basis of satisfactory controlling of the tumor, normalization of hormonal level, and symptomatic improvement of the patient. Several modalities of treatment have been applied and administered, and yet, this disease still remains as inveterate one to be fully treated. The purpose of this study is to evaluate the outcome of gamma knife radiosurgery(GKRS) for GH secreting pituitary adenoma, and to identify various factors affecting the outcome of the treatment. METHOD: A group of 24 out of 35 patients, treated by Leksell gamma knife unit during the period of March of 1992 through October of 1997, had been observed for more than two years. The mean target volume of microadenoma was 449.3mm3(range 216-880mm3), and that of macroadenoma was 3183.1mm3(range 1456-13125mm3). The tumor margin was covered with 50% isodose profile, and mean marginal dose was 25.2Gy(range 15-32.4Gy). The mean number of isocenter was 4.3(range 1-6). The exposed dose to the optic apparatus was less than 8Gy. The mean follow-up period was 37.8months(range 24-102months). RESULT: No patients showed any increase in the tumor volume during the follow-up period. And definite shrinkage of tumor volume(tumor volume reduction rate, TVRR: more than 50%) was obtained in 10 patients(41.7%). Twenty one patients(87.5%) had reduced hormonal level compared than pre-treatment level. Among them, normalization of the hormonal level was achieved in 12 patients(50%). Clinicoendocrinological remission was seen in 3 patients (12.5%). According to the results of statistical analysis, tumor volume(p=0.016),duration of symptoms(p=0.046), initial GH level(p=0.017), and the invasion of cavernous sinus(p=0.036) were significantly favorable to post-radiosurgical outcome. The TVRR was significantly related to post-radiosurgical reduction of serum GH level. Permanent complication was not seen. CONCLUSION: The authors concluded that GKRS is a safe and effective treatment modality for acromegaly. To otain the better outcome of GKRS in GH secreting pituitary adenoma, more careful and sophisticated treatment-planning is recommended.
